

Technology Available for Industry-Academia Collaboration or Technology Licensing.

“DBPR807: a CXCR4-Targeted Antagonist”

Date: 2019.07.24

1. Title:  
NHRI technology, “DBPR807: a CXCR4-Targeted Antagonist”  
(abbreviated as “**The Technology**”) available for industry-academia collaboration or technology licensing.
2. Description:  
DBPR807 is a potent antagonist targeting CXCR4 receptors for medical treatment of peripheral blood stem cell transplantation, hepatocellular carcinoma and acute myocardial infarction.
3. Potential collaboration partner qualifications:
  - (1) be incorporated and approved by law and does not have any record of misconduct or conviction for any offense
  - (2) better to have related experience and skills for developing **The Technology**
  - (3) better to have experience of international collaboration and clinical trial
  - (4) be willing to provide long-term investment
4. Registration :  
Please contact to Mr. Hua-Hsuan Liang (Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan, R.O.C., Tel: +88637-246166#33206, E-mail: huahsuan@nhri.org.tw).
5. Other:
  - (1) If **The Technology** has been exclusively licensed, this announcement will automatically invalid.
  - (2) NHRI retains the right to modify and terminate this announcement.
  - (3) For detailed status of **The Technology**, please contact to the case officer.

Attachments:

I: Announcement

II: Technology Transfer Vendor Qualification Form

III: Industry-Academia Collaboration Proposal